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Neurologists of the ENCALS centers throughout
Europe have discussed the potential of edaravone as a
new therapy for amyotrophic lateral sclerosis (ALS,
Motor Neuron Disease, MND) at the ENCALS
meeting, 18–20 May 2017, in Ljubljana, Slovenia.
In May 2017, the US Food and Drug
Administration (FDA) granted a license for the
drug known as edaravone (licensed in Japan in 2015
as Radicut) for the treatment of ALS in the United
States (to be marketed as Radicava). We are not
aware of any official request fromMitsubishi Tanabe
Pharma, the manufacturer of edaravone, to the
European Medicines Agency (EMA) to register the
drug for use in ALS in Europe. However, edaravone
can be imported to Europe from Japan or the
United States.
The FDA approval of edaravone is based on a
single positive clinical trial. The ENCALS neurolo-
gists were of the view that the outcome of this trial
requires a balanced and considered interpretation
when considering how best to advise those with ALS
and their families. This study showed that edaravone
may slow disease progression in ALS, but the disease-
modifying effect was limited to a subgroup of ALS
patientswith distinct clinical characteristics. For ALS
patients without those characteristics there is cur-
rently no evidence for a therapeutic benefit of
edaravone.
What is edaravone?
Edaravone is a free radical scavenger originally
developed for treatment of stroke, and is adminis-
tered intravenously (IV). Patients receive the drug
every day for 2 weeks, then take a break (‘drug
holiday’) for 2 weeks, followed by 10-d sessions of
treatment every month. Ideally, the first 2 treatment
courses should be administered in a hospital for
safety reasons, including potential side-effects and
reactions to the drug.
What is known about the effectiveness of
edaravone?
Japanese clinicians working with Mitsubishi Tanabe
Pharma ran a 9-month study of edaravone, which
included a 3-month observational period followed
by a 6-month test period. This double-blind placebo
controlled trial involved over 200 people with ALS,
half of whom were randomized to receiving the
drug, and half to a placebo treatment. This trial did
not show any statistically significant benefit in favor
of the drug, although there was a trend towards
slower disease progression in the people taking the
drug. This hint of an effect led the investigators to
analyze the data more thoroughly, and they identi-
fied a subgroup of people that appeared to obtain
some benefit. Subsequently, the investigators carried
out an additional smaller study focused on patients
with clinical characteristics of this subgroup only.
These were people who had mild to moderate
involvement of swallowing, fine motor function
and gross motor function measured using the ALS
functional rating scale (ALSFRS-R), with symptoms
in 3 of 4 body regions (arms, legs, bulbar and
thorax, as inclusion was restricted to definite ALS
according to the El Escorial criteria), within 2 years
of symptom onset, and with normal respiratory
function. Enrolment took place across many sites in
Japan over a 2-year period, and a total of 130 people
were recruited. This trial showed a statistically
significant slowing of disease progression as assessed
using the ALSFRS-R over the 24-week treatment
period in those taking edaravone.
The facts about edaravone
 The positive study was based on a small group
of people with ALS who fulfilled very specific
criteria before they could be enrolled in the trial.
Within this group, those who received edara-
vone as part of the study experienced a
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reduction in the rate of disease progression.
Those taking edaravone declined by 5.1 points
on the ALSFRS-R scale over 6 months,
compared with those on placebo, who declined
by 7.5 points. Previous studies have shown that
most people with ALS decline by about 5.6
points over 6 months.
 The effect of edaravone on muscle strength and
respiratory function is not clear.
 There is no known effect of edaravone on
quality of life.
 No studies of the effect of edaravone after 6
months have been published yet.
 Due to the short study period (6 months) no
survival data were collected.
 Treatment with edaravone is cost- and labor-
intensive, with daily infusions for at least 10 d in
the first 2 weeks of every month although in
some countries, doctors can arrange drug
administration off site from hospital settings.
 Intravenous (IV) injection of edaravone can
be via a PICC line, Port-A-Cath, cannula
(eg venflon) or butterfly, and it can take up to
an hour for each daily infusion to be completed.
 It is recommended that at least the first 2 sets of
infusion courses are administered in a hospital
because of possible side-effects and the risk of a
reaction to the drug.
 The costs of edaravone are more than E1000
per patient per month plus the cost of giving the
infusions. Reimbursement of these costs by
health services will depend on the health struc-
ture within each country. In some countries, the
drug will not be funded by the existing health
system, and the person with ALS will be
required to pay for the treatment.
Decision making on edaravone treatment
Weighing up the pros and cons of edaravone
treatment should be made on an individual basis,
taking into account how closely the patient matches
the trial clinical criteria, the therapeutic goals of the
affected person, and their personal resources. Given
the mode of drug application with frequent intra-
venous infusions, treatment with edaravone is
associated with considerable time expenditure for
patients and their care givers. The therapeutic
benefits of edaravone treatment must be balanced
against the potential burden of an intravenous route
for the application of the drug.
The opinion of ENCALS
While the results of the studies are encouraging,
questions regarding the effectiveness of edaravone
remain:
1. Is edaravone beneficial to patients who are more
severely affected than those who participated in the
study?
2. Is the effect maintained if taken for more than 6
months?
3. Does edaravone affect survival?
The consensus view of the ENCALS neurolo-
gists is that an extended clinical trial with at least
12 months followup, including analysis of effects on
survival, is indicated to resolve these questions, and
to ensure that appropriately selected patients with
ALS have maximum opportunities to avail them-
selves of a potentially beneficial therapeutic agent.
ENCALS invites MT Pharma to conduct a trial
in Europe
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